CD276 and prostate carcinoma: To test this concept, we assessed the immunostimulatory effects of XmAb808 combined with an EpCAM×CD3 bispecific antibody in cocultures of T cells with B7-H3+ EpCAM+ 22Rv1 human prostate carcinoma cells.